388 related articles for article (PubMed ID: 27231794)
1. Comparative Assessment of Medical Resource Use and Costs Associated with Patients with Symptomatic Peripheral Artery Disease in the United States.
Chase MR; Friedman HS; Navaratnam P; Heithoff K; Simpson RJ
J Manag Care Spec Pharm; 2016 Jun; 22(6):667-75. PubMed ID: 27231794
[TBL] [Abstract][Full Text] [Related]
2. Antiplatelet Therapy and Clinical Outcomes Following Myocardial Infarction Among Patients in a U.S. Employer-Based Insurance Database.
Patel MD; Wu D; Chase MR; Mavros P; Heithoff K; Hanson ME; Simpson RJ
J Manag Care Spec Pharm; 2017 Jun; 23(6):684-690. PubMed ID: 28530518
[TBL] [Abstract][Full Text] [Related]
3. Resource use and costs in high-risk symptomatic peripheral artery disease patients with diabetes and prior acute coronary syndrome: a retrospective analysis.
Reed Chase M; Friedman HS; Navaratnam P; Heithoff K; Simpson RJ
Postgrad Med; 2016; 128(2):170-9. PubMed ID: 26788980
[TBL] [Abstract][Full Text] [Related]
4. Health care resources and costs for treating peripheral artery disease in a managed care population: results from analysis of administrative claims data.
Margolis J; Barron JJ; Grochulski WD
J Manag Care Pharm; 2005; 11(9):727-34. PubMed ID: 16300416
[TBL] [Abstract][Full Text] [Related]
5. Effect of Apixaban Versus Warfarin Use on Health Care Resource Utilization and Costs Among Elderly Patients with Nonvalvular Atrial Fibrillation.
Deitelzweig S; Luo X; Gupta K; Trocio J; Mardekian J; Curtice T; Lingohr-Smith M; Menges B; Lin J
J Manag Care Spec Pharm; 2017 Nov; 23(11):1191-1201. PubMed ID: 29083968
[TBL] [Abstract][Full Text] [Related]
6. Clinical and economic burden in patients with diagnosis of peripheral arterial disease in a claims database in Japan.
Hosaka A; Miyata T; Onishi Y; Liao L; Zhang Q
Clin Ther; 2014 Aug; 36(8):1223-30, 1230.e1-4. PubMed ID: 25012730
[TBL] [Abstract][Full Text] [Related]
7. Real-World Economic Outcomes During Time on Treatment Among Patients Who Initiated Sunitinib or Pazopanib as First Targeted Therapy for Advanced Renal Cell Carcinoma: A Retrospective Analysis of Medicare Claims Data.
Vogelzang NJ; Pal SK; Ghate SR; Li N; Swallow E; Peeples M; Zichlin ML; Meiselbach MK; Perez JR; Agarwal N
J Manag Care Spec Pharm; 2018 Jun; 24(6):525-533. PubMed ID: 29799328
[TBL] [Abstract][Full Text] [Related]
8. Economic Burden of Irritable Bowel Syndrome with Diarrhea: Retrospective Analysis of a U.S. Commercially Insured Population.
Buono JL; Mathur K; Averitt AJ; Andrae DA
J Manag Care Spec Pharm; 2017 Apr; 23(4):453-460. PubMed ID: 28345443
[TBL] [Abstract][Full Text] [Related]
9. Stenting for peripheral artery disease of the lower extremities: an evidence-based analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2010; 10(18):1-88. PubMed ID: 23074395
[TBL] [Abstract][Full Text] [Related]
10. Economic burden of irritable bowel syndrome with constipation: a retrospective analysis of health care costs in a commercially insured population.
Doshi JA; Cai Q; Buono JL; Spalding WM; Sarocco P; Tan H; Stephenson JJ; Carson RT
J Manag Care Spec Pharm; 2014 Apr; 20(4):382-90. PubMed ID: 24684643
[TBL] [Abstract][Full Text] [Related]
11. Economic burden of coronary artery disease or peripheral artery disease in patients at high risk of ischemic events in the French setting: a claims database analysis.
Emery C; Torreton E; Briere JB; Evers T; Fagnani F
J Med Econ; 2020 May; 23(5):513-520. PubMed ID: 31928390
[No Abstract] [Full Text] [Related]
12. Medical costs and resource utilization for hemophilia patients with and without HIV or HCV infection.
Tencer T; Friedman HS; Li-McLeod J; Johnson K
J Manag Care Pharm; 2007; 13(9):790-8. PubMed ID: 18062730
[TBL] [Abstract][Full Text] [Related]
13. Clinical and Economic Burden of Commercially Insured Patients with Acromegaly in the United States: A Retrospective Analysis.
Placzek H; Xu Y; Mu Y; Begelman SM; Fisher M
J Manag Care Spec Pharm; 2015 Dec; 21(12):1106-12. PubMed ID: 26679960
[TBL] [Abstract][Full Text] [Related]
14. Patient Outcomes, Health Care Resource Use, and Costs Associated with High Versus Low HEDIS Asthma Medication Ratio.
Luskin AT; Antonova EN; Broder MS; Chang E; Raimundo K; Solari PG
J Manag Care Spec Pharm; 2017 Nov; 23(11):1117-1124. PubMed ID: 29083971
[TBL] [Abstract][Full Text] [Related]
15. Patients with Idiopathic Membranous Nephropathy: A Real-World Clinical and Economic Analysis of U.S. Claims Data.
Nazareth TA; Kariburyo F; Kirkemo A; Xie L; Pavlova-Wolf A; Bartels-Peculis L; Vaidya N; Sim JJ
J Manag Care Spec Pharm; 2019 Sep; 25(9):1011-1020. PubMed ID: 31283419
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of clinical characteristics, health care resource utilization, and cost outcomes of hemophilia A carriers and noncarriers in the United States: A real-world comparative analysis.
Xing S; Batt K; Kuharic M; Bullano M; Caicedo J; Chakladar S; Markan R; Farahbakhshian S
J Manag Care Spec Pharm; 2023 Jun; 29(6):626-634. PubMed ID: 37276033
[No Abstract] [Full Text] [Related]
17. Patient Support Program Increased Medication Adherence with Lower Total Health Care Costs Despite Increased Drug Spending.
Brixner D; Rubin DT; Mease P; Mittal M; Liu H; Davis M; Ganguli A; Fendrick AM
J Manag Care Spec Pharm; 2019 Jul; 25(7):770-779. PubMed ID: 31081461
[TBL] [Abstract][Full Text] [Related]
18. Impact of a Patient Support Program on Patient Adherence to Adalimumab and Direct Medical Costs in Crohn's Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Psoriatic Arthritis, and Ankylosing Spondylitis.
Rubin DT; Mittal M; Davis M; Johnson S; Chao J; Skup M
J Manag Care Spec Pharm; 2017 Aug; 23(8):859-867. PubMed ID: 28737994
[TBL] [Abstract][Full Text] [Related]
19. Impact of cardiovascular disease on health care economic burden and resource utilization: a retrospective cohort study in adults in the United States with type 2 diabetes with or without stroke, myocardial infarction, and peripheral arterial disease.
King A; Rajpura J; Liang Y; Paprocki Y; Uzoigwe C
Curr Med Res Opin; 2022 Nov; 38(11):1831-1840. PubMed ID: 36134459
[TBL] [Abstract][Full Text] [Related]
20. Patient Characteristics, Health Care Resource Utilization, and Costs Associated with Treatment-Regimen Failure with Biologics in the Treatment of Psoriasis.
Foster SA; Zhu B; Guo J; Nikai E; Ojeh C; Malatestinic W; Goldblum O; Kornberg LJ; Wu JJ
J Manag Care Spec Pharm; 2016 Apr; 22(4):396-405. PubMed ID: 27023693
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
